Bio-Techne (TECH) News Today

Bessemer Group Inc. lifted its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 117.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,776 shares of the biotechnology company's stock after buy

Clearbridge Investments LLC reduced its holdings in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 1.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,057,644 shares of the biotechnology company's stock

Vanguard Group Inc. boosted its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 0.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,272,433 shares of the biotechnology company's stock after purc

Edgestream Partners L.P. acquired a new position in Bio-Techne Co. (NASDAQ:TECH - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 57,547 shares of the biotechnology company's stock, valued at approxim

Bio-Techne Co. (NASDAQ:TECH - Free Report) - Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Bio-Techne in a note issued to investors on Thursday, July 18th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per s

Lord Abbett & CO. LLC lifted its position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 6.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 278,468 shares of the biotechnology com

Blair William & Co. IL decreased its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 17.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 99,280 shares of the biotechnology company's stock after selling 21,323 shares during the

US Bancorp DE cut its stake in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 16.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,936 shares of the biotechnology company's stock after selling

Susquehanna Fundamental Investments LLC bought a new position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,800 shares of the biotechnology co

FORA Capital LLC bought a new position in Bio-Techne Co. (NASDAQ:TECH - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 23,748 shares of the biotechnology company's stock, valued at approximately $1,672,000. Other large investors h

Sumitomo Mitsui Trust Holdings Inc. lowered its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 1.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,424,484 shares of the biotechnology company's stock aft

Bio-Techne Co. (NASDAQ:TECH - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy re

Allspring Global Investments Holdings LLC reduced its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 1.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,288,157 shares of the biotechnology company's stoc

Vanguard Group Inc. reduced its position in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,228,210 shares of the biotechnology company's stock after

PNC Financial Services Group Inc. boosted its stake in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 8.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 144,710 shares of the biotechnology company's stock after purchasi

Polen Capital Management LLC bought a new position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,383 shares of the biotechnology company's

Harbert Fund Advisors Inc. acquired a new position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biotechnology company's stock, valued at a

Mairs & Power Inc. raised its position in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,079,483 shares of the biotechnology company's stock after buyin

Oribel Capital Management LP bought a new position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 116,800 shares of the biotechnology

Advanced Portfolio Management LLC acquired a new stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 22,028 shares of the biotechnology company's stock, valued at approximately $1,700,000. Bio-Techne accounts fo

Tower Research Capital LLC TRC raised its holdings in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 152.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,378 shares of the biotechnology company

First Trust Advisors LP raised its stake in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 27.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 739,694 shares of the biotechnology company's stock a

Shares of Bio-Techne Co. (NASDAQ:TECH - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy ra

Public Employees Retirement Association of Colorado boosted its stake in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 7,628.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21

Rhenman & Partners Asset Management AB decreased its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 62.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,000 shares of the biotechnology company's stock af

Stephens Investment Management Group LLC lessened its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 688,417 shares of the biotechnology company's stock

UBS Group AG lifted its stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 405.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 142,949 shares of the biotechnology company's stock after acquiring an additional 114,648 shares during the q

Polen Capital Management LLC acquired a new position in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,383 shares of the biotechnology company's stock, valued at a

Bio-Techne (NASDAQ:TECH) Stock Price Down 4%

Artisan Partners Limited Partnership acquired a new stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 285,995 shares of the biotechnology company's stock, valu

Jensen Investment Management Inc. lifted its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 24.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,060 shares of the biotec

S&CO Inc. lifted its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 126.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,710 shares of the biotechnology compan

Norges Bank acquired a new stake in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,552,240 shares of the biotechnology company's stock, valu

Leavell Investment Management Inc. cut its stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 19.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,057 shares of the biotechnology company's stock after selling 12,

Corient Private Wealth LLC increased its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 4,482.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 633,790 shares of the biotechnology company's stock after acqu

Citigroup downgraded shares of Bio-Techne from a "buy" rating to a "neutral" rating and set a $85.00 price objective on the stock. in a research report on Wednesday.